Investors & Media Press Releases

Press Releases

Summary Toggle

02.19.2019

Summary Toggle Axovant to Present at 8th Annual SVB Leerink Global Healthcare Conference

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in a fireside chat at the 8th Annual SVB Leerink
Read More

PDF Version
Read More
Summary Toggle

02.14.2019

Summary Toggle Axovant Announces Formation of Arvelle Therapeutics and Strategic Transition of Legacy Small Molecule Team Into Newly Formed Company

Summary ToggleTransition of small molecule expertise to Arvelle completes transformation of Axovant into a company focused exclusively on gene therapies Axovant will receive a preferred equity stake in Arvelle, which has received commitments of over $100 million in capital from prominent biotechnology investors
Read More

PDF Version
Read More
Summary Toggle

02.07.2019

Summary Toggle Axovant Announces Third Fiscal Quarter 2018 Financial Results and Corporate Updates

Summary ToggleExpanded pipeline with two investigational gene therapy programs licensed from the University of Massachusetts Medical School for the treatment of GM1 gangliosidosis, Tay-Sachs and Sandhoff diseases First two patients dosed in SUNRISE-PD phase 2 trial of AXO-Lenti-PD for Parkinson's disease and
Read More

PDF Version
Read More
Summary Toggle

01.03.2019

Summary Toggle Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones

Summary ToggleAxovant’s CEO, Pavan Cheruvu, M.D., will be presenting at the J.P. Morgan Healthcare Conference at 8:00 a.m. PST on Thursday, January 10 th , 2019 Initial clinical data expected in first half of 2019 from the AXO-AAV-GM2 and AXO-Lenti-PD gene therapy programs Axovant assembles Scientific Advisory
Read More

PDF Version
Read More
Summary Toggle

12.14.2018

Summary Toggle Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares

Summary ToggleBASEL, Switzerland , Dec. 14, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price to the public of $1.00 per share. Gross proceeds to Axovant from the offering are expected
Read More

PDF Version
Read More
Summary Toggle

12.13.2018

Summary Toggle Axovant Sciences Announces Public Offering of Common Shares

Summary ToggleBASEL, Switzerland , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXON) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant. In connection with this offering, Axovant expects to
Read More

PDF Version
Read More
Summary Toggle

12.13.2018

Summary Toggle Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School

Summary ToggleTwo novel programs for fatal pediatric diseases deepen Axovant’s neurological gene therapy pipeline AXO-AAV-GM1 expected to enter the clinic in first half 2019, with initial data expected in second half 2019 First patient has been dosed with AXO-AAV-GM2, with initial data expected in first quarter
Read More

PDF Version
Read More
Summary Toggle

12.10.2018

Summary Toggle Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder

Summary TogglePrimary efficacy endpoint assessed by sleep laboratory video assessment was not met Axovant is discontinuing clinical development of nelotanserin BASEL, Switzerland , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON) a clinical-stage gene therapy company, today reported topline
Read More

PDF Version
Read More
Summary Toggle

12.06.2018

Summary Toggle Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson’s Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial

Summary ToggleMeeting with FDA confirmed that studies previously conducted using first generation ProSavin® may be considered part of a single development program with AXO-Lenti-PD Confirmed with FDA that the proposed current manufacturing process and quality control testing is adequate for the clinical program
Read More

PDF Version
Read More
Summary Toggle

11.26.2018

Summary Toggle Axovant Stengthens Team with Additional Expertise to Support Gene Therapy Pipeline

Summary ToggleGreg MacMichael , Ph.D., formerly global head of cell and gene therapy technical development and manufacturing at Novartis , joins Axovant as SVP of technical operations Parag Meswani , Pharm.D., formerly head of U.S. marketing and diagnostics at Spark Therapeutics , joins Axovant as SVP of
Read More

PDF Version
Read More

Investors & Media Press Releases

Press Releases

Email Alerts

Print

Email

Search

Investors & Media Press Releases

Press Releases

Toolbar

Email Alerts

Print

Email

Search